Company news

Share this article:

Eisai hosted a dedication ceremony to commemorate the opening of its newly constructed US corporate headquarters in Woodcliff Lake, NJ. The three-story facility will provide Eisai with 209,000 square feet of space and capacity for more than 700 people to accommodate its ongoing expansion and anticipated future growth. The dedication ceremony was attended by Eisai executives and state and local dignitaries, including Soichi Matsuno, deputy president and executive officer, Eisai; Hajime Shimizu, president, Eisai Corporation of North America and chairman and CEO; and Lonnel Coats, President & COO, Eisai. Other notable guests included New Jersey Governor Jon Corzine, and Billy Tauzin, president and CEO of the Pharmaceutical Research and Manufacturers of America.

Novavax has agreed with Allergan to terminate its manufacturing supply agreement for Estrasorb. The drug was previously licensed by Novavax to Esprit Pharma (recently acquired by Allergan, Inc.) in 2006 and is an approved estrogen product for relief of moderate to severe vasomotor symptoms (hot flashes) associated with menopause. Under the termination agreement, Novavax will complete the manufacture of remaining orders for the product and plans to close its Philadelphia manufacturing facility over the next few months. Allergan will continue to sell Estrasorb for the foreseeable future from available inventory. Additionally, Allergan will return to Novavax the rights to develop ESP 210, an investigational drug in Phase II development for the treatment of hypoactive sexual desire disorder.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.